[go: up one dir, main page]

NO975726D0 - N-Hydroksyurea-derivater som anti-inflammatoriske midler - Google Patents

N-Hydroksyurea-derivater som anti-inflammatoriske midler

Info

Publication number
NO975726D0
NO975726D0 NO975726A NO975726A NO975726D0 NO 975726 D0 NO975726 D0 NO 975726D0 NO 975726 A NO975726 A NO 975726A NO 975726 A NO975726 A NO 975726A NO 975726 D0 NO975726 D0 NO 975726D0
Authority
NO
Norway
Prior art keywords
pct
inflammatory agents
sec
compounds
date
Prior art date
Application number
NO975726A
Other languages
English (en)
Other versions
NO310288B1 (no
NO975726L (no
Inventor
Akemi Ando
Rodney W Stevens
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Priority to NO19975726A priority Critical patent/NO310288B1/no
Publication of NO975726D0 publication Critical patent/NO975726D0/no
Publication of NO975726L publication Critical patent/NO975726L/no
Publication of NO310288B1 publication Critical patent/NO310288B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/10—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO19975726A 1994-05-19 1997-12-05 N-hydroksyurea-derivater som anti-inflammatoriske midler, anvendelse derav og farmasöytisk preparat NO310288B1 (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO19975726A NO310288B1 (no) 1994-05-19 1997-12-05 N-hydroksyurea-derivater som anti-inflammatoriske midler, anvendelse derav og farmasöytisk preparat

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP12810594A JP3179286B2 (ja) 1994-05-19 1994-05-19 Ｎ−ヒドロキシ尿素系抗炎症剤
CA002223023A CA2223023C (en) 1994-05-19 1995-06-07 N-hydroxyureas as antiinflammatory agents
PCT/JP1995/001127 WO1996040659A1 (en) 1994-05-19 1995-06-07 N-hydroxyureas as antiinflammatory agents
NO19975726A NO310288B1 (no) 1994-05-19 1997-12-05 N-hydroksyurea-derivater som anti-inflammatoriske midler, anvendelse derav og farmasöytisk preparat

Publications (3)

Publication Number Publication Date
NO975726D0 true NO975726D0 (no) 1997-12-05
NO975726L NO975726L (no) 1998-02-03
NO310288B1 NO310288B1 (no) 2001-06-18

Family

ID=27170556

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19975726A NO310288B1 (no) 1994-05-19 1997-12-05 N-hydroksyurea-derivater som anti-inflammatoriske midler, anvendelse derav og farmasöytisk preparat

Country Status (19)

Country Link
US (1) US5814648A (no)
EP (1) EP0832078B1 (no)
JP (2) JP3179286B2 (no)
AT (1) ATE185803T1 (no)
AU (1) AU705505B2 (no)
BR (1) BR9502072A (no)
CA (1) CA2223023C (no)
CZ (1) CZ286331B6 (no)
DE (1) DE69512940T2 (no)
DK (1) DK0832078T3 (no)
ES (1) ES2138211T3 (no)
FI (1) FI974444A7 (no)
GR (1) GR3032301T3 (no)
HU (1) HUT77950A (no)
IL (1) IL113706A (no)
NO (1) NO310288B1 (no)
NZ (1) NZ287551A (no)
PL (1) PL179853B1 (no)
WO (1) WO1996040659A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19548419A1 (de) * 1995-12-22 1997-06-26 Bayer Ag Substituierte Thiazoline
US20030129186A1 (en) 2001-07-25 2003-07-10 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US7790720B2 (en) 2005-03-31 2010-09-07 Ucb Pharma, S.A. Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses
CN101287411B (zh) 2005-04-28 2013-03-06 普罗秋斯生物医学公司 药物信息系统及其用途
WO2008036682A2 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
DK3395372T3 (da) 2009-02-20 2022-04-19 Enhanx Biopharm Inc System til afgivelse af glutathion-baseret medikament
SG175390A1 (en) 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
EP2427178B1 (en) 2009-05-06 2023-01-04 Laboratory Skin Care, Inc. Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
WO2021214048A1 (en) * 2020-04-20 2021-10-28 Johann Wolfgang Goethe-Universität Frankfurt am Main Dual inhibitors of soluble epoxide hydrolase and 5-lipoxygenase

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE144247T1 (de) * 1990-07-25 1996-11-15 Abbott Lab Acetylenderivate mit lipoxygenase inhibitorischer wirkung
JP2528741B2 (ja) * 1991-01-09 1996-08-28 ファイザー製薬株式会社 オキサゾ―ル、チアゾ―ルおよびイミダゾ―ル化合物
JPH07100687B2 (ja) * 1991-06-13 1995-11-01 ファイザー製薬株式会社 新規なｎ−ヒドロキシ尿素化合物および組成物
US5288751A (en) * 1992-11-06 1994-02-22 Abbott Laboratories [(Substituted) phenyalkyl]furylalkynyl-and [substituted) phenyalkyl] thienylalkynyl-N-hydroxyurea inhibitors or leukotriene biosynthesis
WO1994022814A1 (en) * 1993-04-07 1994-10-13 Pfizer Inc. Cycloalkylhydroxyureas and their use as lipoxygenase inhibitors

Also Published As

Publication number Publication date
IL113706A0 (en) 1995-08-31
CA2223023A1 (en) 1996-12-19
WO1996040659A1 (en) 1996-12-19
DK0832078T3 (da) 2000-04-25
NO310288B1 (no) 2001-06-18
NZ287551A (en) 1999-02-25
FI974444A0 (fi) 1997-12-05
FI974444L (fi) 1998-02-04
DE69512940D1 (de) 1999-11-25
EP0832078A1 (en) 1998-04-01
MX9709986A (es) 1998-03-29
CZ286331B6 (cs) 2000-03-15
HUT77950A (hu) 1998-12-28
CA2223023C (en) 2001-07-17
AU705505B2 (en) 1999-05-27
IL113706A (en) 1999-08-17
JPH10506649A (ja) 1998-06-30
DE69512940T2 (de) 2000-02-17
PL324012A1 (en) 1998-04-27
ATE185803T1 (de) 1999-11-15
ES2138211T3 (es) 2000-01-01
US5814648A (en) 1998-09-29
GR3032301T3 (en) 2000-04-27
EP0832078B1 (en) 1999-10-20
JP3179286B2 (ja) 2001-06-25
AU2629495A (en) 1996-12-30
NO975726L (no) 1998-02-03
CZ382497A3 (cs) 1999-03-17
FI974444A7 (fi) 1998-02-04
BR9502072A (pt) 1996-04-09
PL179853B1 (pl) 2000-11-30
JPH07309849A (ja) 1995-11-28

Similar Documents

Publication Publication Date Title
ZA919317B (en) Novel hydroxamic acid and N-hydroxyurea derivatives and their use.
ATE206123T1 (de) Phenylxanthin-derivate
EA200100376A1 (ru) Арилсульфонанилидмочевины
TR199802060T2 (xx) Aminoisokinolinler ve aminopiridin t�revlerinin iltihap �nleyiciler olarak kullan�m�.
NO975726D0 (no) N-Hydroksyurea-derivater som anti-inflammatoriske midler
RU94038256A (ru) Производные пиразолопиримидина, способ их получения, фармацевтические композиции на их основе
FI972434A0 (fi) Lamotrigiiniä sisältävä farmaseuttinen koostumus
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
FI932654A0 (fi) Hydroxamsyraderivat, som hindrar lipoxigenas
EA199700150A1 (ru) КОМБИНИРОВАННОЕ ЛЕЧЕНИЕ ПО ПОВОДУ ВИЧ ИНФЕКЦИИ С ИСПОЛЬЗОВАНИЕМ ИНГИБИТОРА ПРОТЕАЗЫ ВИЧ ИНДИНАВИРА И ИНГИБИТОРА ОБРАТНОЙ ТРАНСКРИПТАЗЫ 3TC, НЕОБЯЗАТЕЛЬНО СОВМЕСТНО С AZT, ddI ИЛИ ddC
ATE309803T1 (de) Sphingomyelinase inhibitoren als wirkstoffe mit antiapoptotischer und antiseptischer wirkung
DE69413831D1 (de) Phenoxyphenylcyclopentenyl-hydroxyharnstoffe
ATE190845T1 (de) Rektale flunisolid-zubereitung zur behandlung entzündlicher darmerkrankungen
SE9902596D0 (sv) Pharmaceutically active compounds

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees